论文部分内容阅读
目的:研究血清Wilms瘤基因(WT1)和多药耐药基因1(MDR1)的表达与多发性骨髓瘤疾病程度的相关性。方法:采用实时荧光PCR技术对30例不同期多发性骨髓瘤患者及30例健康者静脉血清进行WT1与MDR1基因表达水平检测,并分析其表达量与多发性骨髓瘤疾病程度的影响。结果:多发性骨髓瘤患者的血清WT1与MDR1基因表达水平均明显高于普通健康者,差异具有统计学意义(P<0.05);多发性骨髓瘤分期越高,患者血清WT1与MDR1基因的表达水平则越高,Ⅰ期、Ⅱ期与Ⅲ期患者的血清WT1与MDR1基因的表达水平两两组间比较差异均具有统计学意义(P<0.05);WT1与MDR1基因表达水平与骨髓瘤分期呈明显的正相关性(r=0.406,r=0.451,P<0.05)。结论:血清WT1与MDR1基因表达水平与多发性骨髓瘤疾病程度具有明显的正相关性,可能作为多发性骨髓瘤的临床评估预测指标。
Objective: To investigate the relationship between the expression of serum Wilms’ tumor gene (WT1) and multidrug resistance gene 1 (MDR1) and the degree of multiple myeloma disease. Methods: The real-time fluorescent PCR was used to detect the expression of WT1 and MDR1 in venous serum of 30 patients with multiple myeloma and 30 healthy controls. The expression levels of WT1 and MDR1 were analyzed by real-time fluorescence PCR. Results: The levels of WT1 and MDR1 gene in patients with multiple myeloma were significantly higher than those in normal controls (P <0.05). The higher the stage of multiple myeloma, the expression of WT1 and MDR1 The levels of WT1 and MDR1 in patients with stage Ⅰ, Ⅱ and Ⅲ were significantly different between the two groups (P <0.05). The expression levels of WT1 and MDR1 were correlated with the stage of myeloma There was a significant positive correlation (r = 0.406, r = 0.451, P <0.05). Conclusion: The expression levels of WT1 and MDR1 in serum are positively correlated with the degree of multiple myeloma and may be used as predictors for the clinical evaluation of multiple myeloma.